CD274 and non-small cell lung carcinoma: Current clinical trials mostly utilize anti-TIGIT regimens as an addition to anti-PD-1/PD-L1 or anti-CTLA-4 inhibition, with few exceptions: a Phase I trial in which vibostolimab is administered to anti-PD-1/PD-L1-refractory NSCLC (NCT02964013), a Phase II trial in which vibostolimab is utilized in treatment naïve advanced NSCLC (NCT04165070), and a terminated Phase I trial which used etigilimab in advanced/metastatic solid malignancies, lung included (NCT03119428).